Celgene CELG reported second-quarter earnings of $2.86 per share, which beat the analyst consensus estimate of $2.63 by 8.75%. This is a 32.41% increase over earnings of $2.16 per share from the same period last year.
The company reported quarterly sales of $4.4 billion, which beat the analyst consensus estimate of $4.23 billion by 4.02%. This is a 15.36% increase over sales of $3.814 billion the same period last year.
Celgene also raised fiscal year 2019 guidance: adjusted EPS from $10.60-$10.80 to $10.65-$10.85 versus a $10.73 estimate; and sales from $17 billion-$17.2 billion to $17.2 billion-$17.4 billion versus a $17.11 billion estimate.
Celgene shares are trading up 1.09% at $94 in Tuesday’s pre-market session. The stock has a 52-week high of $98.97 and a 52-week low of $58.59.
Related Links:
The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
